Seres Therapeutics (NASDAQ:MCRB) Downgraded to Underweight at JPMorgan Chase & Co.

Seres Therapeutics (NASDAQ:MCRB) was downgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a note issued to investors on Thursday, MarketBeat.com reports.

MCRB has been the subject of several other research reports. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Friday, September 13th. Finally, Chardan Capital restated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, August 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Seres Therapeutics currently has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Trading Down 3.3 %

NASDAQ:MCRB opened at $0.76 on Thursday. The stock has a 50 day moving average of $0.90 and a two-hundred day moving average of $0.91. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $2.05. The firm has a market cap of $114.65 million, a P/E ratio of -1.26 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same period in the previous year, the firm earned $0.36 EPS. On average, research analysts forecast that Seres Therapeutics will post -0.95 earnings per share for the current year.

Insider Buying and Selling at Seres Therapeutics

In other news, insider Teresa L. Young sold 24,480 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $1.08, for a total transaction of $26,438.40. Following the sale, the insider now owns 78,178 shares of the company’s stock, valued at approximately $84,432.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 28,844 shares of company stock valued at $30,104 in the last three months. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Seres Therapeutics

A number of large investors have recently modified their holdings of MCRB. Mirae Asset Global Investments Co. Ltd. acquired a new position in Seres Therapeutics during the 1st quarter worth $39,000. Providence Wealth Advisors LLC grew its position in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after buying an additional 25,250 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Seres Therapeutics during the second quarter worth approximately $64,000. Virtu Financial LLC acquired a new stake in Seres Therapeutics in the first quarter valued at approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the second quarter valued at approximately $92,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.